TheraPanacea is a highly innovative information technology company devoted to unlocking the unlimited power of AI-based solutions to drive innovation in healthcare. Spinoff of University of Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge. Our technology is a unique combination of decisional, domain-constrained, and data-driven artificial intelligence software equipping clinicians and healthcare professionals with the most innovative tools to improve treatment selection, planning, delivery, and outcomes, including biomarker discovery and patient stratification. Using TheraPanacea’s AI-powered clinical solutions (ART-Plan™), healthcare providers experience significant gain in productivity, higher standardization of care, improvement of clinical workflow and better treatment outcomes for cancer patients. TheraPanacea’s AI-powered biomarker discovery platform (ART-Omics™) offers upstream/downstream innovation to pharmaceutical companies through shorter development cycles, decreased costs and higher efficacy.